Evidence map›Paper›PMID 37250720›Full record

ArticlePeerJ2023

PFI-3 induces vasorelaxation with potency to reduce extracellular calcium influx in rat mesenteric artery.

Jing Li, Xue-Qi Liang, Yun-Feng Cui, Yu-Yang Fu, Zi-Yue Ma, Ying-Tao Cui, Xian-Hui Dong, Hai-Jun Huang, Ting-Ting Tong, Ya-Mei Zhu and 4 more

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Jing LiDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Xue-Qi LiangDepartment of Pharmacy, Second Affiliated Hospital of Qiqihar Medical College, Qiqihar, Heilongjiang Province, China.
Yun-Feng CuiDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Yu-Yang FuDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Zi-Yue MaDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Ying-Tao CuiDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Xian-Hui DongDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Hai-Jun HuangDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Ting-Ting TongDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Ya-Mei ZhuDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Ya-Dong XueDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Yong-Zhen WangDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Tao BanDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Rong HuoDepartment of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China.
Harbin Medical University · CNQiqihar Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: PFI-3 is a small-molecule inhibitor that targets the bromodomains (BRDs) of Brahma-related gene 1 (BRG1). This monomeric compound, which has high selectivity and potent cellular effects, has recently been developed. Although PFI-3 has been reported as a potential therapeutic agent targeting thrombomodulin, its role in the regulation of vascular function remains unknown. Therefore, we aimed to investigate the impact of PFI-3 on arterial vessel tone. Methods: A microvascular tension measurement device (DMT) was utilized to identify alterations in vascular tension within the mesenteric artery. To detect variations in cytosolic [Ca Results: PFI-3 exerted a dose-dependent relaxation effect on rat mesenteric arteries with both intact and denuded endothelium after phenylephrine (PE)- and high-K Conclusions: PFI-3 blunted PE and high K

Indexed as

CalciumFluorescent DyesAniline CompoundsAnimalsBenzeneacetamidesCalcium Channels, L-TypeMesenteric ArteriesPiperidonesRatsXanthenesAniline Compoundsantineoplaston A10BenzeneacetamidesCalciumCalcium Channels, L-TypeFluo-3Fluorescent DyesPiperidonesXanthenesCalcium channelsPFI-3VasoconstrictionVasodilation

Identifiers

PMID37250720
PMCPMC10225122
OpenAlexW4378226708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.